The drug is expected to cater to the fast growing Rheumatoid Arthritis, Plaque Psoriasis, JIA, Psoriatic Arthritis, Ankylosing Spondylitis, Ulcerative Colitis, Crohns disease, HS and Uveitis markets
~96% decline reported in Malaria cases in Madhya Pradesh, due to public-private-people partnership
First PARP inhibitor to demonstrate clinical benefit in radiographic progression-free survival in combination with a new hormonal agent with or without homologous recombination repair gene mutations
Collaboration supports multiple discovery efforts, including vaccines
Collaboration focuses on developing and implementing real-world research to drive patient access to cancer medicines
The card-to-cloud device was launched into the U.S. and many other markets and is designed to work without an embedded communications module.
Company appoints five new independent directors to reconstituted board
All claims made by Seagen regarding Daiichi Sankyo antibody drug conjugates are denied
Investment in response to increased demand for North American-based chemistry services
The company has reported total income of Rs. 1607.85 crores during the period ended June 30, 2022.
Subscribe To Our Newsletter & Stay Updated
